Dr. Tithi Parija
Associate Professor
Dr. Tithi Parija began her academic career after completing her M.Sc. and M.Phil. in Zoology from Utkal University. She earned her Ph.D. in Molecular Oncology from Institute of Life Sciences ( BRIC-ILS), Bhubaneswar and subsequently received a Postdoctoral Fellowship from the Department of Biotechnology. Prior to joining KIIT University, she worked at Sri Ramachandra Medical College and Research Institute and Cancer Institute (WIA) , Chennai. She is a recipient of the Young Scientist Award from the DST, Odisha and the DBT-BioCARe Women Scientist Award. Her research focuses on the molecular mechanisms underlying breast, colon and oral carcinogenesis, with particular emphasis on the evaluation of naturally derived bioactive compounds as potential anticancer therapeutics and drug resistance.
EDUCATIONAL QUALIFICATION
PhD in Life Sciences
COURSE EXPERTISE
Cell Biology, Animal Physiology, Molecular Diagnosis and Precision Medicine, Animal and Medical Biotechnology
RESEARCH INTERESTS
Apoptosis and cell signaling, Natural product based anticancer therapeutics, Cancer stem cells, Drug resistance
Administrative Responsibilities
Faculty in charge of Tutor Mentor Program and Student Internship and Dissertation
Awards and Achievements
Young Scientist Award, DST, Odisha in 2002
Professional Membership
Life Member of
• Indian Association of Cancer Research( IACR)
• Indian Science Congress(ISC)
• Molecular Pathology Association of India(MPAI)
• Indian Society of Translational Research(ISTR)
Projects & Consultancies
As PI
• Quinacrine inhibits metastasis and angiogenesis in oral cancer stem cells through the inhibition of tumor associated macrophages derived inflammatory cytokines (ICMR, 2023-2026).
• Study on Estrogen Receptor – alpha on breast cancer with reference to local population (DBT, 2013-2016).
As Co-PI
• Olaparib (AZD2281) a PARP inhibitor and curcumin synergistically induces apoptosis in oral cancer stem cells by inhibiting the DNA repair cascade (DBT, 2018-2021).
• Bioprospecting of selected lichen and plant species for Product Development against cancer and Tuberculosis (DBT, 2007-2012).